POLX Share Price Performance
UK£0.0008
0.00 (0.00%)
98.0% undervalued intrinsic discount
UK£0.04
Fair Value
Price UK£0.0008
AnalystConsensusTarget UK£0.04
Fair ValueUK£0.04
Share Pricen/a
Polarean Imaging plc Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
POLX Community Narratives
AN
Fair Value
·Fair Value UK£0.04 98.0% undervalued intrinsic discount
Pharma Trials And Pediatric FDA Approval Will Open Global Markets
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Pharma Trials And Pediatric FDA Approval Will Open Global Markets
Key Takeaways New revenue vertical in pharma-sponsored trials and FDA approval for younger patients expand market opportunities and potential revenue streams. Successful reimbursement pathway and international expansion indicate future growth and reduced financial risk.Read more
AN
UK£0.04
98.0% undervalued intrinsic discount
Fair Value
Profit Margin
8.43%
Future PE
46.63x
Price in 2028
UK£0.037
Trending Discussion
Recently Updated Narratives
AN
Pharma Trials And Pediatric FDA Approval Will Open Global Markets
Fair Value: UK£0.04 98.0% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Polarean Imaging plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.008
- 45.21%
- -374.12%
- 0%
About POLX
- Founded
- 2016
- Employees
- 26
- CEO
- WebsiteView website
Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; chest coil; Polarean 9820 Xenon hyperpolarizer that is designed to deliver up to 3 litres of hyperpolarized 129Xe per hour; and Polarean 2881 polarization measurement station, which provides a calibrated measurement of the polarization of hyperpolarized gas within the dose delivery inhalation bag. Polarean Imaging plc was incorporated in 2016 and is based in London, the United Kingdom.
